Conflict of interest statement: Conflict of interest statement: H. Iznardo does 
not have any potential conflicts of interest involving the work under 
consideration for publication. L. Puig has perceived consultancy/speaker’s 
honoraria from and/or participated in clinical trials sponsored by Abbvie, 
Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, 
JS BIOCAD, Leo-Pharma, Lilly, Merck-Serono, MSD, Mylan, Novartis, Pfizer, 
Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi, and UCB. Receipt of 
grants/research supports or participation in clinical trials (paid to 
institution): Abbvie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Janssen, 
Leo-Pharma, Lilly, Novartis, Pfizer, Regeneron, Roche, Sanofi, UCB. Receipt of 
honoraria or consultation fees (paid to myself): Abbvie, Almirall, Amgen, 
Baxalta, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, 
Fresenius-Kabi, Janssen, JS BIOCAD, Leo-Pharma, Lilly, Mylan, Novartis, Pfizer, 
Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi, UCB. Participation in a 
company sponsored speaker’s bureau: Celgene, Janssen, Lilly, Novartis, Pfizer. 
Stock shareholder: None. Other support (please specify): None.